1. Int J Mol Sci. 2016 Dec 18;17(12):2132. doi: 10.3390/ijms17122132.

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in 
Non-Small Cell Lung Cancer.

Tomasini P(1)(2), Serdjebi C(3)(4), Khobta N(5), Metellus P(6), Ouafik L(7)(8), 
Nanni I(9), Greillier L(10)(11), Loundou A(12), Fina F(13), Mascaux C(14)(15), 
Barlesi F(16)(17).

Author information:
(1)Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & 
Therapeutic Innovations department. Aix Marseille University, Marseille 13015, 
France. pascale.tomasini@ap-hm.fr.
(2)Inserm U911 CRO2 (Centre de Recherche en Oncologie biologique et 
Onco-pharmacologie), Aix Marseille University, Marseille 13005, France. 
pascale.tomasini@ap-hm.fr.
(3)Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & 
Therapeutic Innovations department. Aix Marseille University, Marseille 13015, 
France. cindy.serdjebi@univ-amu.fr.
(4)Assistance Publique Hôpitaux de Marseille, Transfer Oncology Laboratory, Aix 
Marseille University, Marseille 13015, France. cindy.serdjebi@univ-amu.fr.
(5)Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & 
Therapeutic Innovations department. Aix Marseille University, Marseille 13015, 
France. nataliyasantoni@hotmail.com.
(6)Department of Neurosurgery, Aix-Marseille University, Marseille 13005, 
France. philippe.metellus@outlook.fr.
(7)Inserm U911 CRO2 (Centre de Recherche en Oncologie biologique et 
Onco-pharmacologie), Aix Marseille University, Marseille 13005, France. 
L'houcine.OUAFIK@ap-hm.fr.
(8)Assistance Publique Hôpitaux de Marseille, Transfer Oncology Laboratory, Aix 
Marseille University, Marseille 13015, France. L'houcine.OUAFIK@ap-hm.fr.
(9)Assistance Publique Hôpitaux de Marseille, Transfer Oncology Laboratory, Aix 
Marseille University, Marseille 13015, France. Isabelle.NANNI@ap-hm.fr.
(10)Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & 
Therapeutic Innovations department. Aix Marseille University, Marseille 13015, 
France. laurent.greillier@ap-hm.fr.
(11)Inserm U911 CRO2 (Centre de Recherche en Oncologie biologique et 
Onco-pharmacologie), Aix Marseille University, Marseille 13005, France. 
laurent.greillier@ap-hm.fr.
(12)Statistics Department, Aix Marseille University, Marseille 13005, France. 
anderson.loundou@univ-amu.fr.
(13)Assistance Publique Hôpitaux de Marseille, Transfer Oncology Laboratory, Aix 
Marseille University, Marseille 13015, France. frederic.fina@ap-hm.fr.
(14)Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & 
Therapeutic Innovations department. Aix Marseille University, Marseille 13015, 
France. celine.mascaux@ap-hm.fr.
(15)Inserm U911 CRO2 (Centre de Recherche en Oncologie biologique et 
Onco-pharmacologie), Aix Marseille University, Marseille 13005, France. 
celine.mascaux@ap-hm.fr.
(16)Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & 
Therapeutic Innovations department. Aix Marseille University, Marseille 13015, 
France. fabrice.barlesi@ap-hm.fr.
(17)Inserm U911 CRO2 (Centre de Recherche en Oncologie biologique et 
Onco-pharmacologie), Aix Marseille University, Marseille 13005, France. 
fabrice.barlesi@ap-hm.fr.

BACKGROUND: Lung cancer is the leading cause of brain metastases (BM). The 
identification of driver oncogenes and matched targeted therapies has improved 
outcome in non-small cell lung cancer (NSCLC) patients; however, a better 
understanding of BM molecular biology is needed to further drive the process in 
this field.
METHODS: In this observational study, stage IV NSCLC patients tested for EGFR 
and KRAS mutations were selected, and BM incidence, recurrence and patients' 
outcome were assessed.
RESULTS: A total of 144 patients (142 Caucasian and two Asian) were selected, 
including 11.27% with EGFR-mutant and 33.10% with KRAS-mutant tumors, and 57.04% 
patients had developed BM. BM incidence was more frequent in patients with EGFR 
mutation according to multivariate analyses (MVA) (Odds ratio OR = 8.745 
[1.743-43.881], p = 0.008). Among patients with treated BM, recurrence after 
local treatment was less frequent in patients with KRAS mutation (OR = 0.234 
[0.078-0.699], p = 0.009). Among patients with untreated BM, overall survival 
(OS) was shorter for patients with KRAS mutation according to univariate 
analysis (OR = 7.130 [1.240-41.012], p = 0.028), but not MVA.
CONCLUSIONS: EGFR and KRAS mutations have a predictive role on BM incidence, 
recurrence and outcome in Caucasian NSCLC patients. These results may impact the 
routine management of disease in these patients. Further studies are required to 
assess the influence of other biomarkers on NSCLC BM.

DOI: 10.3390/ijms17122132
PMCID: PMC5187932
PMID: 27999344 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no conflict of interest.